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1. Introduction 
A number of reviews have been written on this subject 
and related topics in the last 10 years to which the reader 
will be referred in relevant sections. However, Edwards 
[62] provides a good overview of neutrophil physiology 
and Rossi [170] has provided an excellent account of the 
early work. The emphasis placed in this review reflects the 
research interests and personal bias of the authors; a 
paper-by-paper account of all that has been published, in 
any field, is likely to be dull to the point of indigestibility. 
All circulating blood cells, despite their widely differing 
morphology, are derived from one pluripotent, 
haematopoietic stem cell population located in the red 
bone marrow of bones (vertebrae, fibs, sternum, skull and 
long bones) which comprise 2-3% of body weight. Ery- 
throcytes, responsible for the transport of O 2 to and CO 2 
from the tissues, are the predominant cell type, outnumber- 
ing leucocytes (white blood cells) by 1000:1. Collectively, 
the leucocytes are responsible for the defence of the body 
against infection and are subdivided into neutrophils (3700 
cells/mm3), lymphocytes (2500 cells/mm3), monocytes 
(400 cells/ram3), eosinophils (150 cells/mm 3) and ba- 
sophils (30 cells/ram3). The different classes of lympho- 
cytes produce antibodies in response to an infection and 
serve as the immune system memory, whereas neutrophils, 
monocytes and eosinophils participate in the cellular im- 
mune response by engulfing, killing and digesting invading 
organisms. Neutrophils and monocytes are bactericidal, 
whereas eosinophils deal with parasites. The cytoplasm of 
neutrophils, eosinophils and basophils (collectively termed 
granulocytes) is rich in secretary granules which can be 
released following activation. Basophils contain histamine 
and serotonin which, when released, give rise to the imme- 
diate hypersensitivity reaction (allergic response). The cy- 
toplasmic secretary granules of neutrophils and eosinophils 
contain proteinases, cytotoxic proteins and chelators 
utilised during the killing and digestion of foreign bodies. 
Platelets, derived from megakaryocytes, participate inblood 
clotting and wound healing. All blood cells have a limited 
lifespan, which varies from many years for lymphocyte 
memory cells, through 120 days for erythrocytes to a few 
days in the case of neutrophils, and therefore have to be 
continuously replaced at an appropriate rate from the pool 
of maturing cells within the bone marrow [4,62]. Errors in 
the regulation of this replacement, both natural and in- 
duced, result in a number of disorders including leukaemias 
and lymphoma. 
Neutrophils are the initial participants in the cellular 
defence of the body. They contain a characteristic large, 
multi-lobed nucleus (thus their other name, polymorphonu- 
clear leucocytes), a cytoplasm rich in three types of gran- 
ule (azuorphilic, specific and tertiary), [11,22,139,191] but 
little endoplasmic reticulum, golgi apparatus and few mito- 
chondria. Differentiation and maturation i the bone mar- 
row takes 10 or 11 days. Once in the blood, unstimulated 
neutrophils are either in free circulation or marginally and 
reversibly attached to the endothelial cells of the blood 
vessel wall. Upon bacterial invasion, the neutrophils exit 
the bloodstream through transiently generated gaps be- 
tween the endothelial cells (diapedesis) and migrate ac- 
tively towards the site of infection, where they engulf 
(phagocytosis) and kill the bacteria. The process of phago- 
cytosis continues until the bacterium is completely inter- 
nalised, surrounded by membrane in the phagosome, into 
which the contents of the granules are discharged. A large 
burst in oxygen consumption, the respiratory burst, occurs 
concomitantly. The encounter is normally lethal for both 
bacterium and neutrophil. The resulting debris is cleared 
by macrophages which arrive later. 
2. Respiratory burst 
A large burst in oxygen consumption by neutrophils 
during phagocytosis was first observed by Baldridge and 
Gerard [12]. It has been shown to be insensitive to in- 
hibitors of the respiratory chain of mitochondria (HCN, 
antimycin), and to be associated with an increase in 
metabolism through the hexose monophosphate shunt. It is 
now accepted that this increased oxygen consumption is
due to the activity of the NADPH oxidase which catalyses 
the reaction: 
NADPH + 202 ~ NADP++ 20~ + 2H + 
The oxidase activity which is quiescent in resting cells 
may be stimulated in vitro within 15 to 60 s by a wide 
variety of compounds, including phorbol esters (PMA), 
heat-aggregated IgG (HAGG), unsaturated fatty acids and 
analogues of bacterial peptides (fMLP). The burst is tran- 
CYTOSOL MEMBRANE OUTSIDE 
NADPH +H~p~~ FAD B ---" O'~ 
Em= -280mV Em= -245mv Em= -160mV 
Em= -320mv 
p91 + p22 
PROTON CHANNEL 
H + 
Fig. 1. Diagrammatic representation f the NADPH oxidase components 
and associated H+-channel. The NADPH oxidase is composed of a 
heterodimeric, low-potential cytochrome b (gp91-phox +p22-phox) and 
cytosolic proteins which translocate to the membrane upon activation 
(p67-phox, p47-phox and p21ra~). The generation of superoxide involves 
the transfer of an electron from cytosolic NADPH, through FAD and 
haem, to external oxygen. This process is electrogenic and requires the 
efflux of H + ions through a channel to act as charge compensator. The 
redox potential of the cytochrome is atypically low for a b-type cy- 
tochrome but enables the reduction of oxygen to superoxide. 
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Table 1 
g m and turnover 
ated cell systems 
numbers for the NADPH oxidase in whole and fraction- 
System Substrate K m (/~M) Turnover Reference 
number (cyt b/s)  
Neutrophils NADPH 6.06 [84] 
Neutrophils NADPH 20-30 [ 137]a 
permeabilised 
Cytoplasts NADPH 26.67 [84] 
Cell-free NADPH 28.4 65 [99] 
reconstitution NADH 
B-lymphocyte NADPH 30.5 13.75 [77] 
cell lines NADH 341 8.33 
Detergent- 
extracted NADPH 45 18.38 [41 ]
oxidase NADH 460 n.d. 
Relipidated NADPH 75 23.8 [114] 
cytochrome b NADH 1860 n.d. 
occurs with an incidence of 1:250000 to 1:500000 of the 
European population and prior to the discovery of antibi- 
otics lead to death following infection within the first year 
of life. The discovery that neutrophils from CGD patients 
failed to mount a respiratory burst [98,161] identified the 
NADPH oxidase as the genetic lesion involved in CGD 
and thereby significantly advanced the study of the NADPH 
oxidase and the diagnosis and treatment of CGD patients. 
Both X-linked and autosomal recessive patterns of inheri- 
tance have been demonstrated for this disease (Table 2). 
The use of cells from CGD patients has greatly aided the 
study of the different components of the NADPH oxidase. 
Chronic granulomatous disease and its genetics have been 
extensively covered in a recent reviews [44,168,203]. 
4. Assay for NADPH oxidase 
sient in nature, reaching a maximum rate at 3 min after 
stimulation and being undetectable above background after 
30 to 60 min post stimulation [170,14]. The oxidase activ- 
ity of whole cells shows a high Q10, being virtually 
inactive at 25°C but reaching maximal activity at 38°C 
[84]. The basis of the enzyme mechanism is the utilisation 
of electrons from cytosolic NADPH to perform the single 
electron reduction of external oxygen (02 ) to the free 
radical, superoxide (02-);  Fig. 1. Superoxide is highly 
reactive and very short-lived. In solution it rapidly dis- 
mutes to H202, which can by a number of further reac- 
tions lead to the generation of OH- ,  hydroxyl radical, 
singlet oxygen and hypochlorous acid. The K m values and 
turnover numbers for the oxidase in various systems with 
NADPH or NADH are shown in Table 1. 
3. Chronic granulomatous disease 
Chronic granulomatous disease (CGD) is an inherited 
condition in which the affected individuals express a in- 
creased susceptibility to bacterial and fungal infections. It 
Table 2 
Different lesions giving rise to chronic granulomatous di ease 
Type CGD Genetic lesion % of Gene locus Cellular 
total GCD location 
X-linked 
cyt b - re  gp91-phox 60 Xp21.1 membrane 
Autosomal 
recessive 
cyt b - ve p22-phox 5 16q24 membrane 
Autosomal 
recessive 
cyt b +ve p47-phox 30 7ql 1.23 cytosol 
Autosomal 
recessive 
cyt b +ve p67-phox 5 lq25 cytosol 
There are a number of assays for the detection of 
superoxide generation and hence the activity of the NADPH 
oxidase. In all cases it is important hat the progress of 
02 - generation be followed continuously and that with 
whole cells and cytoplasts the temperature be maintained 
at 38°C. The following methods are in current use: 
(a) The superoxide dismutase (SOD)-inhibitable reduc- 
tion of cytochrome c, in which the unpaired electron of 
O2- reduces cytochrome c and causes an increase in 
absorbance at 550 nm. This may be done either by conven- 
tional spectrophotometry or using a micro plate reader. 
(b) Chemiluminescence arising due to the interaction of 
O2- or a dismutation product, with luminol or lucigenin 
which results in the emission of light, using a luminome- 
ter. This assay system has also been adapted for use on a 
microplate reader. 
(c) Nitroblue tetrazolium reduction (NBT) is usually 
performed on a few cells on a microscope slide and 
counterstained with eosin. The basis of the assay is that 
02- or, more likely a product, donates electrons to the 
water-soluble NBT, resulting in the formation of the 
water-insoluble, coloured formazan. The assay is the test 
used in the identification of patients and carders of CGD. 
(d) Oxygen consumption detected using an oxygen 
electrode shows a dramatic increase following stimulation 
of the oxidase. Care has to be exercised to ensure that 02 
consumption by other means, e.g., mitochondria, is ex- 
cluded by using suitable inhibitors. 
(e) Changes in fluorescent properties of a number of 
dyes have been exploited for the detection of the activity 
of the oxidase, e.g., scopieotin, dihydrorhodamine 123. 
However, these are assays for H20 2 production and there- 
fore are indirect assays and not absolutely specific for O2-. 
(f) Species-specific spin trap probes, whose presence is 
detected by the use of EPR. 
In all cases it is necessary to initiate the activity of the 
oxidase by the addition of an appropriate concentration of 
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a stimulus and it is prudent o ensure the specificity of the 
activity by use of an inhibitor. The method of choice is 
certainly the reduction of cytochrome c, as this is least 
likely to result in artifacts. 
5. Cell types producing superoxide 
The activity of the oxidase can be measured, by one of 
the above assays, in neutrophils, eosinophils, macrophages 
either isolated from whole blood or recovered from the 
peritoneal cavity following the elicitation of an immune 
response (peritoneal cells), in neutrophils i olated from the 
inflamed joints of a rheumatoid patients (synovial fluid 
neutrophils) and in macrophages recovered by lavage of 
the lungs (alveolar macrophages). With these cells super- 
oxide generation can be elicited in isolated whole cells, 
enucleated cells (cytoplasts), permeabilised cells, in a 
cell-free reconstitution system and a modified reconstitu- 
tion system using a combination of purified and recombi- 
nant protein components. Neutrophils are normally isolated 
from whole blood or the buffy coat fraction (concentrated 
white blood cells). They are readily isolated in high num- 
bers (109 per pint blood) by means of centrifugation 
through a selective density gradient. 
Cytoplasts are enucleated, agranular, right-side-out 
derivatives of cells which, despite lacking the internal 
organelles of their parent cell retain their important func- 
tional characteristics. Cytoplasts can be generated from 
neutrophils in large numbers on a discontinuous step gradi- 
ent of Ficoll. They express a stimulatable NADPH oxidase 
activity and retain an ability to undergo chemotaxis and 
phagocytosis [169]. As they are single-compartment cells, 
they have been exploited in studies in which the unequivo- 
cal cellular location of the dyes was important [82] and in 
studies dissecting the relative contribution of superoxide 
and the granular contents to the process of killing [148]. 
The technique of electroporation [71,72,112] and a 
number of bacterial toxins (streptolysin O, a-toxin) 
[13,100] have been utilised to permeabilise cells, facilitat- 
ing access to the interior. However, none of the permeabil- 
isation techniques is 100% efficient (some whole cells 
always remain) and the holes also permit the leakage of 
cytosolic omponents and cofactors out of the cell. In fact, 
recent studies have made use of this loss of cytosol to 
explore the requirements for the maintenance of the oxi- 
dase activity [32]. 
The use of the cell-free reconstitution system was first 
reported in 1984 [23,91] and involves the recombination f
the membrane and cytosolic fractions isolated from un- 
stimulated cells following disruption by sonication [158]. 
The elicitation of oxidase activity requires the presence of 
GTP-y-S [66,123,155], Mg 2÷ and is activated by the 
addition of an unsaturated fatty acid (arachidonate) or SDS 
[24,45,123,186]. The membrane and cytosolic fractions 
from different sources can be recombined in a heterolo- 
gous cell-free system [35]. A further refinement of the 
cell-free reconstitution system has been the development 
of the use of purified or recombinant, relipidated mem- 
brane components of the oxidase combined with recombi- 
nant cytosolic proteins to demonstrate he absolute require- 
ment or enhancement of oxidase activity achieved by the 
inclusion of a known protein [1,2,135,172,173]. The bro- 
ken cell assay systems are relatively unstable at 37°C and 
are therefore normally monitored at 25°C. 
6. Cells used in the study of the oxidase by tissue 
culture 
Of blood cells which express the oxidase only mono- 
cytes can be maintained in culture for some time (7-14 
days). They grow in size but are incapable of cell division. 
Other blood cells survive only a matter of few hours in 
vitro and must be used the same day. However, there are a 
small number of immortal cell lines which either constitu- 
tively express the oxidase or in which the expression can 
be induced. Some of these are: 
(a) Isolated B lymphocytes immortalised following 
transformation with Epstein-Barr virus (EBV-transformed 
lymphocytes) can be maintained as a suspension i  culture 
and express the components of the oxidase constitutively 
[208]. Low levels of oxidase activity can be triggered by a 
number of compounds, including those that cross linking 
Fc receptors, interleukin 1 a, phorbol esters [77,127]. The 
lag time following addition of the stimulus is longer than 
that observed for the neutrophil oxidase and superoxide 
generation is sustained for longer (2 h). 
(b) A human myeloid cell line, HL60, isolated in 1977 
from a patient with acute promyelocytic leukaemia [36]. 
The cells are characterised aspromyelocyte, grow continu- 
ously in suspension and can be induced to differentiate 
into neutrophil by addition of dimethylsulfoxide (DMSO) 
or dimethylformamide (DMF) or into macrophages by 
1,25-dihydroxyvitamin D 3, PMA or sodium butyrate 
[21,37,38,81]. The process of differentiation into neu- 
trophils requires 5 to 7 days and is associated with an 
increase in the expression of the components of the oxi- 
dase correlated with an increase in the activatable superox- 
ide generation [121,130,143,167]. Unfortunately, the dif- 
ferentiated cells are no longer immortal. 
(c) PLB-985 are a diploid human myelomonoblastic cell 
line derived from patient with relapsed myeloid leukaemia 
[205,216]. This cell line has very similar properties to 
those described for HL60 cells. 
(d) U937 are exclusively a monocyte cell line in which 
the expression of the oxidase components and superoxide 
generation can be induced by PMA, all-trans-retinoic acid, 
vitamin D3, interferon-y together with tumour necrosis 
factor-a [81,109,195]. 
(e) THP-1 are also a monocyte cell line derived from 
young patient with acute monocytic leukaemia which can 
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be induced to express the oxidase [204]. They have been 
utilised to prepare cDNA libraries. 
7. Components of the oxidase 
The identification of the components of the oxidase was 
facilitated by the availability of cells from CGD patients 
and the availability of complementation assays (cell fusion 
[76] and cell-free reconstitution system). It is now widely 
accepted that the oxidase consists of a membrane-span- 
ning, heterodimeric cytochrome b consisting of a large 
/3-subunit (gp91-phox) and a smaller c~-subunit (p22-phox) 
associated with two proteins located in the cytosolic frac- 
tion of unstimulated cells (p47-phox and p67-phox) (Fig. 
!). The cDNA encoding these proteins have been cloned 
and sequenced and the chromosomal location has been 
identified [52,53,80,119,126,154,176,198,199,209,215]. 
The corresponding proteins have been purified ; cyto- 
chrome b [180], p67-phox [158]a,[195]a nd p47-phox 
[158]b,[195]b. 
7.1. Cytochrome b 
The absence of a characteristic b-type cytochrome dif- 
ference spectrum (reduced- oxidised) from neutrophils 
isolated from a number of CGD patients uggested a role 
for the b-type cytochrome in the NADPH oxidase 
[179,180]. The differentiation of HL60 cells into neu- 
trophil-like cells is associated with a dramatic increase in 
their ability to generate superoxide in response to stimuli 
and this is exactly paralleled by an increase in cytochrome 
b [121,167]. 
The redox potential is atypically low ( -245  mV) for a 
b cytochrome, but this enables the reduction of oxygen to 
superoxide [40,214]. In a detergent-extracted active oxi- 
dase complex, under anaerobic onditions, in the presence 
of NADPH the cytochrome is only some 10% reduced 
[138]. The rate of electron flow through the b cytochrome 
has been demonstrated to be matched by the rate of 
generation of superoxide [41]. It is thought hat the low- 
level steady-state r duction of the b under anaerobic on- 
ditions indicates a requirement for oxygen binding before 
functional reduction can occur [41]. 
In the neutrophil, the cytochrome b is localised in the 
plasma membrane and in the membrane of the specific 
granules [181] in a ratio of 30:70%. Some authors have 
found even higher amounts in the specific granules [20]. 
There is evidence that some of the cytochrome in the 
specific granules translocates to the plasma membrane or 
membrane of the developing phagolysosome following 
stimulation [34,182]. This suggests that the granules act as 
a reservoir of cytochrome tobe called upon when required, 
although the extent to which this occurs may be small. 
This hypothesis i  supported by the fact that the specific 
granule membrane cytochrome b has been demonstrated to 
be functionally competent when combined with the cytoso- 
lic fraction [29]. Whether the specific granular cytochrome 
pool becomes activated following stimulation but before 
incorporation i to the plasma membrane is not known at 
present, but seems unlikely. 
The X-linked gene responsible for CGD was cloned by 
reverse genetics from a differentiated HL60 cDNA library 
[176]. The predicted product from the cloned gene was a 
polypeptide of 468 amino acids. The lack of sequence 
similarities with other cytochromes cDNAs and the ab- 
~,p91-phox exDressin~ cells (myeloid) 
Low nuclear level of  CDP 
( gp91-phox mRNA " ] ,, 
2CAAT 
2p91-phox non expressing cells 
~CDP prevents binding of CP1 
No gp91-phox mRNA 
3CAAT 
Fig. 2. Proposed mechanism for the restriction of gp91-phox expression to myeloid cells. The 1.5 kb upstream region of gp91-phox promoter contains a
duplicated CCAAT box. In myeloid cells the expression of gp91-phox is facilitated/promoted by the binding of the DNA-binding protein, CPI, to the 
distal CCAAT box. In non-myeloid cells the expression of gp91-phox is suppressed by the interaction of CDP (CCAAT displacement protein) with the 
promoter, excluding the binding of CP1. Nuclear extracts of myeloid cells have much reduced levels of CDP compared to those from non-myeloid cells. 
This 1.5 kb region contains ufficient information to direct the expression of reporter genes to only cells of myeloid lineage. 
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sence of an obvious haem binding site was not consistent 
with a cytochrome. Independently of this, the cytochrome 
was purified from human neutrophils and shown to be a 
heterodimer of ~-subunit (22 kDa) and a /3-subunit (broad 
band 70-110 kDa indicative of glycoprotein) [153,198]. 
The N-linked glycosylation of the /3-subunit s reported to 
be removed by endoglycosidase F treatment, leaving a 
protein which runs with an apparent molecular mass of 55 
kDa on SDS-PAGE [80]. The extent of the reported glyco- 
sylation appears to vary between individuals [110] and 
between species from high in human neutrophils to very 
low in guinea pig macrophages [157]. The N-terminal 
amino acid sequence of the /3-subunit [198] corresponded 
to the sequence of the CGD gene as elucidated by Orkin 
and co-workers [176]. It was established that the in vivo 
/3-subunit N terminus is at nucleotide 16 of the cDNA 
sequence, some 306 nucleotides upstream of that originally 
suggested. Independently, the predicted protein sequence 
of the X-CGD gene was used to raise anti-peptide antibod- 
ies. Western blots identified a 90 kDa protein correspond- 
ing to the X-CGD gene [52]. The corrected 5' untranslated 
sequence [189] suggests that the protein is not synthesised 
with a leader sequence, predicting a cytosolic N-terminus. 
The initiating Met is probably removed following transla- 
tion to give the native protein. The hydropathy plot of the 
full-length /3-subunit suggests that it may cross the mem- 
brane 4 or 5 times and has a large hydrophobic C terminal 
domain. However, the precise three-dimensional structure 
of the protein is at present unknown. 
The /3-subunit, gp91-phox appears to be exclusively 
expressed in cells of the myeloid line, as no clear demon- 
stration of gp91-phox (mRNA or protein) in other cells has 
been reported [154,189], in contrast to p22-phox, p47-phox 
and p67-phox [103]. The regulation of its restricted expres- 
sion has been shown to be due in part to regions in the 1.5 
kDa Y-untranslated region of gp9 l-phox gene [189]. The 
region contains a duplicated CCAAT box between nu- 
cleotides - 106 and - 124 and a TATA box at nucleotide 
-30  (Fig. 2). Deletions made in this region revealed an 
interaction between the DNA binding protein, CPI, and the 
distal CCAAT box in cells expressing p91-phox. High 
levels of a second DNA-binding protein, CCAAT displace- 
ment protein (CDP) are found in the nuclear extracts of 
cells not expressing p91-phox. In the presence of CDP 
expression of gp91-phox is repressed, since the binding of 
CDP and CP1 is mutually exclusive. The absence of 
CDP:DNA binding, usually through low levels of CDP 
expression, is a prerequisite for gp91-phox expression. 
Transgenic mice given the construct containing the 1.5 
kb-2.6 kb upstream region of gp91-phox attached to one 
of two reporter genes, human growth hormone or SV40 
early region showed expression restricted to 10% of the 
monocyte. Constructs with deletions in the CCAAT region 
gave greater levels of gene expression in the transgenic 
mice [190]. It can therefore be concluded that 1.5 kb 
upstream region of the gp91-phox is sufficient o target its 
expression to only myeloid cells and that repression of 
expression involves interaction between the DNA binding 
protein CDP and the CCAAT box region. As expression of 
the reporter genes could not be detected in the granulo- 
cytes and expression was only found in 10% of the mono- 
cyte population it can be concluded that this 1.5 kb 
upstream region does not contain all that is required to 
switch on expression. 
The c~-subunit of the cytochrome, p22-phox, was cloned 
and sequenced by Parkos et al. [154] and has a predicted 
molecular mass of 22 kDa. Comparison of the cDNA and 
protein sequence demonstrated that the protein is not syn- 
thesised with a leader sequence. The hydropathy plot 
suggests that the protein may cross the membrane twice. 
That the protein protrudes on both faces of the membrane 
is suggested by the binding of a number of antibodies 
directed against defined sequences within the protein [102]. 
Although the mRNA for the a-subunit has been reported 
to be present in uninduced and DMF induced HL60 cells, 
EBV-transformed B lymphocytes, HeLa cells, HepG2 
(hepatic), K562 (erythroleukaemic) and human endothelial 
cells, the stable expression of the protein was detected only 
in DMF-induced HL60 cells and therefore appears to be 
restricted to cells expressing mRNA for the/3-subunit, .e., 
myeloid cells [154]. CGD patients with a genetic defect in 
p22-phox gene are rare and show an autosomal recessive 
pattern of inheritance (Table 2) [168]. It has been reported 
that CGD patients with a defect in either cytochrome 
subunit gene lack the stable expression of both subunits 
[180,210]. This has been taken to suggest that stable 
expression, i.e., synthesis and insertion into the membrane, 
requires the regulated expression of both. However, the 
level of expression of the mRNA was not reported so it is 
not possible to decide whether the lack of expression of 
the unaffected protein is regulated by the affected protein 
at the level of transcription or translation or whether the 
expressed protein just turned over more rapidly. In con- 
trast, stable expression of gp91-phox occurs in HL60 cells 
lacking p22-phox expression in the presence of a haem 
synthesis inhibitor and in Chinese hamster ovary cells 
transfected with a plasmid containing the cDNA for gp91- 
phox. No expression of p22-phox, p47-phox or p67-phox 
was detected [83]. In EBV-transformed B lymphocyte cell 
lines established from CGD patients with a genetic lesion 
in p22-phox gene, the expression of gp91-phox, although 
lower, is not absent [83,128,159]. That this might be the 
case in vivo is suggested by the presence of gp91-phox 
intermediates in CGD patients lacking expression of p22- 
phox [ 128, 159]. Therefore, the expression gp91-phox does 
not require that of p22-phox. 
7.1.1. Haem moiety binding site 
Low-temperature (4.2 K) EPR spectra of the partially 
purified pig cytochrome showed peaks at g = 2.85, 2.21 
and 1.67 indicative of a haem in low-spin configuration, 
with bis(imidazole) co-ordination [101,206]. However, the 
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determination of which subunit carries the haem moiety 
presents a problem, since the sequence of neither subunit 
of the cytochrome contains regions of homology with 
known cytochromes and other haem-binding proteins. The 
sequence of the c~-subunit contains only one histidine; 
therefore, a single p22-phox subunit cannot contain the 
haem binding site. 
In an attempt o determine the haem-binding subunit, 
Nugent et al. [144] used ionisation inactivation to deter- 
mine the size by following the loss of the characteristic 
cytochrome difference spectrum. It was found that the 
target corresponded to the destruction of a protein of 21 
kDa, possibly p22-phox. In agreement with this observa- 
tion, HL60 cells differentiated in the presence of the haem 
synthesis inhibitor succinylacetone fail to generate super- 
oxide in response to a stimulus and do not show a typical 
cytochrome spectrum. Although these cells express gp91- 
phox, they have no detectable stable expression of p22-phox 
reacting with polyclonal antibodies [83]. Therefore, the 
translation or stable expression of the p22-phox, but not 
gp91-phox, requires the presence of haem, suggesting that 
this subunit contains the haem binding site. If p22-phox 
does contain the haem pocket, then the haem moiety must 
be held between either a dimer of ct-subunits or between a
dimer composed of a- and /3-subunit or even in some 
novel fashion. The number of haem moieties per oxidase 
complex is uncertain. Quinn et al. [162] report that the 
oxidase is a multi-haem complex. 
Z2. Cytosolic factors 
Prior to the development of the cell-free assay system, 
complementation assays with poly(ethylene glycol)-in- 
duced fusion of monocytes from different CGD patients 
demonstrated that there were at least three different genetic 
defects that could give rise to CGD [76]. Therefore, the 
genetic lesions giving rise to CGD were not restricted to 
the cytochrome in the membrane. Segal et al. [178] identi- 
fied a 47 kDa protein which was not phosphorylated upon 
activation of neutrophils from autosomal recessive CGD 
patients. The activity of the cell free reconstitution system 
was known to be enhanced 3-fold by the inclusion of GTP 
or GTP-y-S [66,123,152,186], which indicated the involve- 
ment of a GTP-binding protein in the oxidase. In an 
attempt to purify the oxidase-associated GTP-binding pro- 
tein(s), Clark and co-workers [210] fractionated cytosol by 
passing it through a GTP-column and eluting the bound 
protein with GTP. Polyclonal antibodies raised to the 
eluant of a normal donor were used to detect he absence 
of expression of proteins of apparent molecular mass of 
either 47 kDa or 67 kDa in the neutrophil cytosols of 
cytochrome-b-positive CGD patients [145,210]. Genetic 
defects in p47-phox and p67-phox are reported in 30% and 
5%, respectively, of all CGD patients. 
The amino acid sequence of neither p47-phox nor p67- 
phox contains regions of homology to known flavin- or 
NADPH-binding sites and no detectable FAD has been 
reported to be associated with either isolated protein [27]. 
It is therefore probable that neither of these cytosolic 
proteins acts as the NADPH-oxidase-associated flavo- 
protein, nor do they contain the NADPH binding site. Both 
do, however, contain two regions of homology with the src 
tyrosine kinase SH3 domains. The possible roles for the 
SH3 domains in the oxidase will be discussed in greater 
detail below. 
It has been widely reported that there is a time-depen- 
dent and ongoing increase in the amount of both p47-phox 
and p67-phox in the membrane fraction of the cell follow- 
ing activation of the oxidase, which has been ascribed to a 
translocation of both proteins from the cytosol to the 
membrane [30,31]. However, at best the proportion of 
either recovered in the membrane fraction is 2% of the 
total immunodetectable protein, even 10 min after stimula- 
tion and long after the oxidase has achieved maximal 
activity (around 1 min or less) [3]. This raises the question 
as to why there is an excess of cellular p47-phox and 
p67-phox protein. Dusi et al. [60] have shown that with 
PMA-, fMLP- or Con-A-stimulated human neutrophils 
p47-phox and p67-phox are continuously recruited over 
the period of study (7 min), whereas the rate of 02 
consumption had reached a constant rate within 1 rain. It is 
possible that a given active oxidase complex is capable of 
superoxide production for a limited period of time and that 
the continuous generation of superoxide requires continu- 
ous recruitment of cytosolic factors which represent the 
expendable components of the complex. 
The translocation of both p47-phox and p67-phox fol- 
lowing activation of the oxidase does not occur in cells 
which lack expression of the cytochrome b [95]. This can 
be interpreted as either that the signal necessary for or that 
triggers translocation is not present if a functional oxidase 
cannot be formed, or, much more likely, that translocation 
to the membrane occurs but as the membrane lacks the 
attachment site for the cytosolic factor(s) they do not 
become stably associated and fall back into the cytosolic 
fraction. It is possible to speculate that the attachment site 
is on either or both of the subunits of cytochrome b (see 
below). The translocation of p67-phox does not occur in 
cells from CGD patients lacking p47-phox. However, the 
translocation of p47-phox is unaffected by the absence of 
p67-phox [61,94,149]. It seems that the translocation of the 
two cytosolic factors is a co-ordinated event, either be- 
cause the two factors translocate together as a complex or 
that the attachment of p47-phox to the membrane forms 
the binding site for p67-phox. That the second of these 
possibilities is probably correct is supported by the recent 
observations of Abo et al. [3], in which the translocation of
both p47-phox and rac2a occurred at substimulatable con- 
centrations of fMLP or PMA and that the activity of the 
oxidase correlated with the subsequent translocation of 
p67-phox. Therefore, the translocation of p47-phox pre- 
cedes and is necessary for the translocation of p67-phox. 
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The stoichiometry of the concentration of the components 
of the active oxidase is unknown. 
However, relipidated purified cytochrome alone is capa- 
ble of generating superoxide [114,115], which calls into 
question the function of the cytosolic factors. Is it possible 
that in vivo the cytosolic factors are required to hold the 
conformation of the cytochrome in a form corresponding 
to that of the relipidated cytochrome? At this time the 
function(s) of both cytosolic factors has not been clearly 
identified. 
The second largest group of CGD patients is that which 
arises as a consequence of a genetic lesion in p47-phox. 
Casimir et al. [26] have identified a hot spot for mutations 
located at the first intron exon junction which contains a 
GCGC repeat. A mismatch results in a deletion of one of 
the GC pairs and shifts into frame a stop codon which 
terminates translation prematurely. This deletion mutation 
was reported to be found in three unrelated CGD patients 
lacking the expression of the p47-phox protein. 
7.3. Low-molecular-weight GTP-binding protein 
A wide range of ras monomeric, GTP-binding proteins 
have an important role in cellular functions, including 
protein trafficking through the cell and signal transduction 
pathways involving receptor tyrosine kinase. Like het- 
eromeric GTP-binding proteins, they are active in the 
GTP-bound form. The members of this family and their 
associated GTPase-stimulating proteins (GSP) have been 
reviewed recently by Hall [75], Goud and McCaffrey [70], 
Pfeffer [156], Rothman and Orci and [171] Bokoch and 
Der [16] and their role in the oxidase by Bokoch [17,18]; 
therefore, we will give only a brief account here. 
These proteins are monomeric, have an apparent molec- 
ular mass of 21 kDa, and are members of a family that 
exhibits a high degree of sequence homology, the major 
differences being in the C-terminal ends of the proteins. 
Members of both the ras and rac subfamilies undergo a 
post-translational modification consisting of prenylation of 
the cysteine located four amino acids from C-terminus 
followed by removal of the three C-terminal residues. The 
unaltered proteins are found predominantly in the cytosol 
of unstimulated cells, associated by their prenyl tail with 
GDI, an inhibitory protein of the GDP/GTP exchange. 
An involvement with the NADPH oxidase for this class 
of proteins was first suggested by the co-purification of 
cytochrome b and a 21 kDa protein, immunologically 
identified as rapla [163]. Later and independently, a cy- 
tosolic factor (o-) in addition to p47-phox and p67-phox 
was shown to be required to obtain maximum superoxide 
generation in a cell-free reconstitution system [23,24]. 
o--Factor was subsequently shown to consist of p21 ~"~ and 
its associated GDP-dissociation i hibitor rhoGDI [1]. The 
purified racl protein, added in the GTP form, increased the 
activity of a purified cytochrome with recombinant p47- 
phox and p67-phox by up to 3-fold. This degree of activa- 
tion is in remarkable agreement with that reported for the 
addition of GTP-y-S alone to the cell-free reconstitution 
system [66]. This protein was later identified as rac2A, 
which is expressed in cells of myeloid origin whereas 
racla is more widely expressed. 
From the work of Abo et al. [3] it appears that, in the 
resting unstimulated neutrophil, rac2a is complexed with 
its GDP/GTP exchange protein (rhoGDI), in the GDP- 
bound form, located in the cytosol. Following activation of 
the oxidase, rac2a is found dissociated from its GDI, 
probably in the GTP-bound form, and undergoes a translo- 
cation to the membrane and specific granules [3,131,164]. 
As with the other cytosolic factors discussed above, less 
than 1% of total cellular ac2a was relocated [3]. How this 
is triggered is not known and the function of rac2a in the 
activation and activity of the oxidase is uncertain. It has 
been suggested that he dissociation of rac2a from its GDI 
is triggered by phosphorylation or by the addition of 
arachidonate [1,183]. Compactin is a potent inhibitor of 
3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA), 
which is on the pathway for the biosynthesis of the sub- 
strates for prenylation. HL60 cells differentiated in the 
presence of DMSO and compactin lack the ability to 
generate superoxide and the cytosol from such cells is 
incapable of functioning in a cell-free reconstitution sys- 
tem. The further addition of mevalonic acid in the culture 
medium restored the ability to generate superoxide [19]. 
These experiments provide strong evidence that a prenyl- 
ated rac protein is required in order to achieve maximal 
rates of superoxide generation. 
7.4. p40-phox 
Segal and colleagues have recently described an addi- 
tional protein which 'enhances' the activity of the purified 
recombinant cell-free system above that already described 
[213]. The protein bears a high degree of homology to 
p47-phox and also has two SH3 domains. It is difficult at 
present o judge the extent of involvement of this protein 
in the oxidase and to assign a function to it. However, the 
protein was identified immunologically and reported to 
translocate to the membrane upon activation of the oxidase 
in whole cells and in cell-free reconstitution system. The 
nature of the involvement of this protein in the oxidase 
will be resolved with time. At present, no CGD patients 
with a genetic defect in this protein have been reported. 
7.5. Flavoprotein 
The involvement of a flavin moiety in the active com- 
plex has long been recognised. The addition of FAD but 
not FMN was reported to enhance the activity of the 
detergent-extracted oxi ase [5], whereas inactive analogues 
of FAD were found to be mild inhibitors of oxidase 
activity in these preparations [151,152]. Some authors have 
shown that FAD is required in the cell-free reconstitution 
L.M. Henderson, J.B. Chappell / Biochimica et Biophysica Acta 1273 (1996) 87-107 95 
system. An EPR signal corresponding to a semi-flavin 
radical has been observed in an active oxidase [104]. 
The compound iphenylene iodonium (DPI) is an in- 
hibitor of complex I of mitochondria showing time-depen- 
dent inhibition with a K~ of 100 /~M [164]a. This com- 
pound was subsequently shown to be a more potent in- 
hibitor of the detergent-extracted active NADPH oxidase 
preparation from pig neutrophils (K i 10 /~M) and showed 
a similar time-dependent i hibition [42]. DPI was subse- 
quently shown to inhibit the NADPH oxidase of rat peri- 
toneal macrophages [78], human neutrophils and cytoplasts 
(enucleated cells) [82], EBV-transformed B lymphocytes 
[77,127], differentiated HL60 cells [83] and a cell-free 
reconstitution system derived from human neutrophils 
[58,99]. A number of analogues which were reported in- 
hibitors of mitochondria complex I were also shown to 
inhibit NADPH oxidase, though with a higher K~ value 
than DPI [43]. 
As described above, the steady-state difference spec- 
trum of an active detergent-extracted oxidase preparation, 
recorded in the presence of NADPH, shows only a 10% 
reduction of cytochrome b and a flavin trough correspond- 
ing to flavin reduction [41]. These were both absent from 
spectra which were recorded in the presence of NADPH 
and DPI (10 /~M). This was interpreted as an inability of 
the electrons to enter the oxidase complex and therefore 
that DPI must act at or before the flavoprotein. It was 
assumed that, since DPI was capable of inhibiting the 
oxidase in the already activated etergent-extracted prepa- 
ration, it must act directly upon the oxidase complex itself 
rather than a component of the signal transduction pathway 
for the activation of the oxidase. DPI was less effective an 
inhibitor in the presence of excess (2 raM) NADPH, 
suggesting that there was competition for binding between 
DPI and NADPH. Therefore, DPI was assumed to inhibit 
the NADPH oxidase at the level of or before the flavo- 
protein component [42]. 
In an attempt o identify the NADPH-oxidase-associ- 
ated flavoprotein, Cross and Jones [42] incubated 125I-DPI 
with pig neutrophil extracts. After SDS-PAGE, a number 
of bands showed labelling, but attention was focused on a 
protein of apparent molecular mass 45 kDa [42]. A band of 
similar molecular mass was subsequently demonstrated in 
rat peritoneal macrophages [78], fibroblasts [134], erythro- 
poietin-producing hepatoma cells (Hep G2) [69] and hu- 
man neutrophils. As a consequence of the site of action of 
DPI and its labelling pattern, the 45 kDa band was as- 
sumed to be the flavoprotein of the NADPH oxidase. 
However, these experiments were conducted at a time 
when it was not known that DPI must first be converted to 
a radical before it can inhibit the oxidase (see below) 
[146,147,200]. 
The inhibition of both the mitochondrial complex I and 
NADPH oxidase by DPI is time-dependent at all concen- 
trations tested [164]a. It has been demonstrated that DPI, 
pre-incubated with cells for even long periods of time (1 
h), failed to inhibit the initial burst of oxidase activity. 
Further, the respiratory burst of cells pre-incubated and 
removed from the DPI solution prior to stimulation was 
unaffected [79]. These observations may be taken to sug- 
gest that a change in conformation of the oxidase is a 
pre-requisite for inhibition or that the inhibitory compound 
is not DPI per se but that it requires chemical modification. 
That the latter is the case is supported by a number of 
observations [58,82,146,147,200]. It appears that DPI must 
first be converted to a radical (by the turnover of the 
oxidase, exposure to reducing agents) before reaction can 
occur. Reaction may be with a number of targets varying 
from FAD, haem or proteins. 
Vignais and colleagues have also investigated the inter- 
action of JzsI-labelled DPI and iodonium biphenyl with 
proteins of bovine neutrophils and cell-free reconstitution 
system. They reported a modification in the cytochrome b
spectrum in active oxidase treated with iodonium biphenyl 
or DPI [57,58]. ~25I-DPI labelled a large number of pro- 
teins on SDS-PAGE in resting cells, but there was a 
marked increase in labelling of a 22 kDa band which was 
associated with activity of the oxidase [58]. As suggested 
by its apparent molecular weight and the correlated modifi- 
cation of the cytochrome b spectrum the protein was 
identified as the a-subunit of the cytochrome b (p22-phox). 
The DPI-dependent inhibition of FAD reduction by 
NADPH observed by Cross and Jones [42] is not inconsis- 
tent with the site of action of DPI postulated by Vignais 
and co-workers, since interaction of cytochrome b with 
oxygen is a necessary pre-requisite for the reduction of 
FAD by NADPH [41]. 
Although a specific site of action for DPI in complex 1 
has been reported, [164]a, the DPI radical is highly reac- 
tive. This makes the determination of its site of action 
within the oxidase extremely difficult and uncertain. There 
is no doubt that DPI is an extremely effective and very 
useful inhibitor of superoxide generation, but whether this 
is due to modification of a specific target or whether its 
effects are merely an accumulation of modifications, the 
sum of which renders the enzyme non-functional, is not 
known. The non-specific labelling of proteins by 125I- 
labelled DPI is due presumably to the generation of radi- 
cals by endogenous reductants; ee [57,58]. 
A number of enzyme systems having a cytochrome and 
flavin (FAD) have been shown to be inhibited by DPI, 
e.g., cytochrome P-450, endothelial and macrophage nitric 
oxide synthase, in addition to mitochondrial NADH dehy- 
drogenase. Therefore, DPI is a good inhibitor of FAD 
cytochrome nzyme systems which permit the generation 
of DPI radical [147]. 
7.5. I. Cytochrome b as the flavoprotein 
Within the amino acid sequence of gp91-phox Segal et 
al. [184] and Rotrosen et al. [173] identified regions of 
homology to the NADPH and FAD binding sites of a 
number of other enzymes, the highest degree of homology 
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being with ferredoxin-NADP +reductase. In support of the 
hypothesis that the /3-subunit of the cytochrome is also the 
flavoprotein (flavocytochrome), Segal et al. [184] reported 
a correlation between the levels of haem and the flavin in 
preparations containing widely different amounts of gp- 
91-phox; from inactive and active neutrophils, active neu- 
trophils; from an X-linked CGD patient; an autosomal 
recessive patient; uninduced HL60 cells, which was taken 
to suggest a coexpression of their binding proteins. Unfor- 
tunately the authors did not study induced HL60 cells, 
which show increased expression of the components of the 
oxidase and so should show a parallel increase in haem 
and flavin moieties. Their purified cytochrome had no 
flavin associated with it but could be reflavinated to 20% 
of that of membranes, though the extent of reflavination 
and the ability to generate superoxide was not investigated. 
The photolabile NADPH analogue 2-azido-NADP labelled 
a broad band in the region of the /3-subunit on an SDS- 
PAGE, only when the oxidase was turning over. They 
concluded that the cytochrome was a flavocytochrome and 
that the /3-subunit contains both the FAD and NADPH 
binding sites. 
Photolabelling of neutrophil membranes with [3H] 
arylazido NADPH [56]a or deflavinated membranes with 
[3H]arylazido FAD [56]b have provided convincing evi- 
dence that the oxidase is an NADPH-dependent flavocy- 
tochrome b. The predominantly photolabelled species was 
a 90-100 kDa protein which was established unambigu- 
ously to be the /3-subunit (gp91-phox) by specific immun- 
odetection and deglycosylation. 
In further support of the hypothesis, attention was drawn 
to a CGD patient who showed an X-linked pattern of 
inheritance and whose neutrophils failed to generate super- 
oxide in response to a variety of stimuli but had a normal 
level of cytochrome b [173,184]. Orkin and colleagues [54] 
had demonstrated that the patient had a single-point muta- 
tion proline 414 ~ histidine in the sequence GAGIGYTP- 
FAS, but could not explain why this rendered the protein 
non-functional, except that it may result in an altered 
protein conformation. However, the identification of this 
region of the protein as the possible NADPH-binding site 
may be a more probable explanation for the patient's 
clinical symptoms. 
If the cytochrome is a flavocytochrome, as is widely 
accepted, this would explain the lack of a class of CGD 
patients lacking the flavoprotein only. It also poses the 
question: if the cytochrome contains the flavin, NADPH 
and haem binding sites what is the role and function(s) of 
the cytosolic factors? The flavocytochrome contains all 
that is necessary for the transfer of electrons from NADPH 
to oxygen; therefore can it generate superoxide in the 
absence of the cytosolic factors? It has recently been 
reported that the purified cytochrome from guinea-pig 
macrophages, relipidated with octyl glucoside, was capable 
of generating superoxide at a rate of 23.8 s - j ,  following 
the activation by LDS and in the presence of NADPH and 
FAD [114,115]. Resting cells do not generate superoxide, 
despite the fact that the substrate, lectron acceptor and the 
prosthetic groups are together in the membrane. Therefore, 
in vivo the cytosolic factors may be necessary for altering 
the conformation of one o~" both the subunits of the cy- 
tochrome upon activation. 
Z6. H + channel 
The activation of the NADPH oxidase in human neu- 
trophils and macrophages is associated with a rapid depo- 
larisation of the membrane potential from -60  mV to 
around - 25 to - 20 inV. The depolarisation occurs with a 
wide range of activators of the oxidase, is complete within 
1 min following the addition of the stimulus and is stable 
for periods of more than 10 min. Some authors have also 
observed a small initial hyperpolarisation (5 mV) prior to 
the subsequent depolarisation. Initially it was proposed that 
the change in membrane potential was an effect of the 
signal transduction pathway leading to the activation of the 
oxidase [113,136,196,197], possibly arising as a conse- 
quence of a triggered influx of Ca 2+ ions [211]. However, 
the failure to observe the depolarisation in stimulated 
neutrophils from various CGD patients [118,187,188] is 
not consistent with this hypothesis, since the lesion lies in 
one of the components of the oxidase complex and not in 
the signal transduction pathway. 
Cytoplasts are right-side-out, single-compartment u- 
cleated neutrophils which retain the functions of the parent 
cell, including a fully active PMA- and fMLP-activatable 
NADPH oxidase [82,164]. They retain a resting membrane 
potential at -60  mV and show a rapid depolarisation of 
greater than 40 mV, upon activation of superoxide genera- 
tion. The extent of the depolarisation following the addi- 
tion of PMA was shown to be considerably reduced in the 
presence of DPI, an inhibitor of the oxidase. The addition 
of DPI, following the PMA, resulted in a partial repolarisa- 
tion of the membrane potential [82,84]. These observations 
strongly suggested that the activity of the oxidase con- 
tributed directly to the changes in the membrane potential. 
To generate superoxide, the oxidase passes an electron 
to external oxygen using internal substrate (glucose) 
through NADP-linked dehydrogenase as the donor, i.e., it 
transfers an electron across the membrane. NADPH is a 
hydride ion donor, but cytochrome b is an electron accep- 
tor as is dioxygen. What happens to the H + ion? If it is 
transferred to the external environment, the process is 
electroneutral. If, however, it is retained on the inside, then 
the process shows a net transfer of a negative charge 
outwards, consistent with depolarisation. It was therefore 
proposed that the depolarisation of the membrane potential 
was due to the fact that the transfer of an electron from 
internal NADPH to external oxygen was not synchronised 
with the transfer of a compensating charge, either negative 
inward or positive outward. Therefore, the generation of 
superoxide by the NADPH oxidase is an electrogenic 
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process [82]. It follows from this hypothesis that if a 
neutrophil, macrophage tc. is incapable of generating 
superoxide in response to a stimulus, it is incapable of 
exhibiting a membrane potential depolarisation and this 
therefore provides an explanation for the reported failure 
to observe a depolarisation of membrane potential in neu- 
trophils from CGD patients. As the depolarisation of the 
membrane potential reaches a steady state, not only must 
the movement of a compensating charge occur, but eventu- 
ally, about 1 rain after stimulation, it must exactly balance 
that of the transfer of electrons. 
Thomas and Meech [201] have presented evidence for 
the existence of an H + channel in snail neurones. This 
channel was blocked by addition of Zn 2+ or Cd 2+. In the 
presence of Zn 2+ or Cd  2+ the PMA-stimulated membrane 
potential depolarisation was accelerated and greatly ex- 
tended ( - 60 mV to - 10 mV), suggesting that these metal 
ions delayed the achievement of the balance between the 
flux of the electrons and the proposed charge compensator 
and suggesting the involvement of an H + channel. That an 
effiux of H + might act as the charge compensating ions 
was further suggested by the observation that the extent of 
the PMA-triggered membrane potential depolarisation 
could be dramatically altered by the extent of transmem- 
brane pH gradient. The depolarisation was smaller if the 
cytoplasts were stimulated in an alkaline medium and 
greater if stimulated in an acid solution. The larger the 
driving force for the efflux of H + ions, the smaller the 
extent of the membrane potential depolarisation and simi- 
larly in the presence of an inward pH gradient he potential 
depolarisation was greatly enhanced [82]. These observa- 
tions all suggested that H + were directly involved in the 
charge compensation for the electrogenic generation of 
superoxide, i.e,, an effiux of H + through a channel com- 
pensates for the activity of the oxidase (Fig. 1). The 
proposed presence of an H + channel facilitates the mainte- 
nance of superoxide by compensating for the effiux of 
electrons while also preventing a dramatic fall in internal 
pH i. However, initially the two transmembrane fluxes are 
asynchronous, one lagging behind that of the other. 
The internal pH (pH i) of neutrophils and a number of 
other cells has been investigated by preloading the pH-sen- 
sitive fluorescent dye, BCECF (2',7'-bis(2-carboxyethyl)- 
5-(and -6-)carboxyfluorescein) i to the cytosol by means 
of its lipid-soluble acetoxyester. Cleavage by cellular es- 
terases exposes four negative charges which effectively 
traps the dye in the cell [166]. The response of the dye can 
be calibrated by alterations in the external pH (pH o) of the 
cells in the presence of the electroneutral H+:K + ex- 
changer, nigericin [202]. This strategy has been exploited 
by a number of workers to monitor changes in pH i, of 
many cells including neutrophils [73,74,117,212] and cyto- 
plasts [85]. Neutrophils maintain a resting pH i of 7.3 
(approx. 0.1 pH units below that of pH o) [73,74,85]. 
However, stimulation of the oxidase is associated with a 
small fall in pH i (0.1 pH unit in 1 min) followed by a 
gradual alkalinisation to 0.2 pH units above that of the 
resting cell, over the following 5 min [73,85]. As the 
generation of superoxide utilises NADPH, the stimulation 
of the oxidase is associated with an increase in pentose 
phosphate pathway activity and hence an increased release 
of CO 2. Amiloride, and a number of derivatives, are 
inhibitors of Na ÷ ion fluxes through channels or cotrans- 
porters including the Na + :H + exchanger. The extent of the 
acidosis following the triggering of the oxidase was slightly 
increased in the presence of amiloride, or one of it deriva- 
tives, and no alkalinisation was observed over 5 min, 
suggesting that the Na +:H + exchanger contributes to the 
recovery from the acid load imposed by the generation of 
superoxide [74,85]. 
It follows from the above hypothesis of an electrogenic 
oxidase and an associated H + channel that in the presence 
of inhibitors of the channel or if an alternative ion is 
permitted to act as the charge compensator for the trans- 
port of electrons, then the fall in internal pH following the 
activation of the oxidase should be greatly enhanced. The 
stimulation of superoxide generation in cytoplasts was 
shown to result in a fall in pHi and this occurred more 
rapidly and to a greater extent in the presence of Zn 2+ or 
Cd 2+ ions (0.25 pH units), in the presence of K-  ionophore 
valinomycin (0.3 pH unit) or in the presence of both 
valinomycin and Zn 2+ or Cd 2+ ions (0.5 pH unit) [85]. 
These observations parallel the changes observed in the 
membrane potential and strongly suggest hat the effiux of 
H + ions occurs through a channel which acts as a charge 
compensator for an electrogenic oxidase. The changes in 
pH o were also consistent with the existence of an H + 
channel, blocked by Zn 2+ or Cd 2. [85]. 
The activity of the oxidase was subsequently shown to 
be tightly coupled to the effiux of H + ions through the 
channel. The inhibition of the channel results in inhibition 
of the superoxide generation. That this was not due to the 
effect of lowered pH~ was demonstrated by the restoration 
of superoxide generation following the provision of an 
alternative charge compensating ion [86]. Therefore, the 
generation of superoxide by the oxidase is dependent upon 
the movement of a compensating ion, normally H +, through 
a channel. However, there is not an absolute requirement 
that the compensating ion be H+; K + and valinomycin 
acted as the charge compensator for the oxidase until other 
factors become limiting. Therefore, the mechanism for the 
transfer of an electron through the oxidase does not require 
the effiux of the H +, nor does the H + channel depend on 
oxidase activity. 
Resting human neutrophils maintain a pH i within 0.1 
pH unit of pH o, despite having a large membrane potential 
(negative inside) which would favour the influx of H + 
ions, presumably because H + ions are pumped out by the 
Na+:H + exchanger and the membrane is relatively imper- 
meable to H+; the channel only opens when activated 
either by such agents as PMA or more directly by arachi- 
donate (see below). As described above, the activation of 
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the oxidase is associated with a rapid depolarisation of the 
membrane potential and an initial fall in pH i , which 
provide a driving force (protonmotive force, Ap) for H + 
effiux. 
The activity of the channel can be monitored in the 
absence of the oxidase activity, thereby easing the study of 
its activation and regulation. For example, exposing cells 
suspended in a high Na + medium to an inward pH gradi- 
ent by rapidly dropping the pH o (pH o < pH i) and/or 
generating a strongly negative membrane potential by the 
addition of valinomycin results in a large driving force for 
the influx of H + ions. Alternatively, in a medium high in 
K + ions and in the presence of valinomycin, conditions 
under which the membrane potential approaches zero, the 
imposition of an outward pH gradient (pHo > pH i) by the 
addition of Tris base provides a driving force for the efflux 
of H + ions. The possibility of either the oxidase or the 
Na +:H + exchanger contributing to the pH changes can be 
prevented by the addition of excess DPI and amiloride 
[87]. By monitoring the channel function in the absence of 
the activity of the oxidase, it was demonstrated that the 
channel was not opened by depolarisation of the mem- 
brane potential, the imposition of a large pH gradient, in 
either direction, or by the imposition of combination of the 
two, Ap. However, in all cases the appropriate change in 
pH~ resulting from the predicted flux of H + ions was 
observed following the addition of arachidonate [87]. As 
arachidonate failed to act as an H + carrier (protonophore, 
uncoupler) in liposomes [87] it was postulated that arachi- 
donate activates the H + channel as with the oxidase itself. 
Arachidonate may open the channel by a direct action 
upon the channel protein(s) or by indirect means, e.g., 
increasing the fluidity of the membrane, allowing protein 
movement or conformation change. In the presence of 
arachidonate, the direction and extent of pH~ changes 
observed is that predicted by the protonmotive force and 
the channel can conduct H + ions in either direction. 
Kapus et al. [106] have reported the measurement of a 
Zn 2+ or Cd 2+ inhibitable H + channel in NH~ pulsed, 
acid-loaded pig neutrophils. They report that the effiux of 
H + ions is 2.5-fold enhanced in the presence of PMA and 
suggest that this results from the PMA directed opening of 
the channel [106]. There is no evidence to suggest hat 
PMA acts directly upon the channel but probably acts 
through its activation of protein kinase C. 
In recent years there have been a number of electro- 
physiological studies of H + conductances in rat epithelial 
cells [47], differentiated HL60 [50], mouse macrophages 
[107] and human neutrophils [48] which have all identified 
the presence of a current ascribed to H +. The outward 
conductance was observed at holding potentials of +60 
mV or higher, with an imposed pH gradient of 1 to 1.5 pH 
units. At a given potential the magnitude of current ob- 
served correlated with the size of the transmembrane pH
gradient. Irrespective of the pH gradient, no current was 
reported at holding potentials at zero or negative potentials 
[48,50,107,108]. It has been concluded on this evidence 
that the H ÷ conductance is voltage-gated. The H ÷ conduc- 
tance was partially blocked by 2 mM to 100 /.tM Cd 2÷ or 
Zn 2÷ in a reversible manner [48,50]. The current was 
restored at higher holding potentials; that is, the presence 
of either Cd 2+ or Zn 2÷ the current voltage (IV) curve 
shifts to the right [48]. Unusually for a channel, there was 
1-2 s delay in opening following the imposition of the 
step to positive holding potentials and, also unlike other 
cation channels, showed no inactivation characteristics, 
i.e., prolonged exposure to high holding potentials does not 
cause closure of the channel [48,50,107]. The recorded 
current was always reported to arise from an efflux of H + 
ions. However, the failure to record current from an influx 
arises probably from technical difficulties rather than an 
absence of this flux. The current observed was enhanced at 
least 3-fold in the presence of 50 /zM or 10 /xM arachi- 
donate, which shifted the current-voltage curve to the left 
[48,108]. That is, the opening of the channel was greater in 
the presence of arachidonate, which allows opening at 
lower potentials than in its absence. This electrophysiolog- 
ical data suggest a rate of flux of 104 H+/s,  which is 
faster than a carrier but slower than normally expected for 
a channel see review [49]. 
From the above description, it will be apparent hat 
there are strong similarities between the putative voltage- 
gated H ÷ channel described in the electrophysiological 
studies and the arachidonate-activatable H + channel de- 
scribed in pH i studies of populations of human neu- 
trophils. Both channels are inhibited by the presence of 
Zn 2+ or Cd 2+, they are activated or enhanced by the 
addition of arachidonate and are present in phagocytes and 
cells expressing the NADPH oxidase. The delay in open- 
ing of the H ÷ channel apparent in electrophysiological 
measurements may be the reason why the membrane is 
depolarised on initiating superoxide generation, since the 
outward conduction of electrons would precede H + trans- 
port. The membrane potential depolarisation was originally 
ascribed to the opening and or initiation of H + efflux 
occurring alter the initiation of superoxide generation. 
However, it is equally true to say that if the channel is 
opened at exactly the same time as or before superoxide is
generated, then an influx of H + ions would occur, driven 
by the negative membrane potential, which it turn would 
give rise to depolarisation. This aspect is currently under 
investigation. 
One marked difference between the results obtained by 
the two approaches i that the electrophysiological studies 
indicate a voltage-gated channel [48,50,107], whereas in 
the pH i studies with BCECF voltage depolarisation failed 
to open the channel; this opening occurred only in the 
presence of arachidonate [87]. In the electrophysiological 
studies, no current was observed at holding potentials of 0 
mV or lower, whereas in the pH i studies arachidonate- 
dependent H ÷ flux occurred at or near zero membrane 
potential (high K + medium together with valinomycin) the 
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direction depending only on ApH. There are problems 
which relate to the methodology of patch clamping. The 
first of these is temperature. Patch clamping experiments 
are carried out routinely at room temperature. Both the 
activation (by PMA, for example) and the activity of the 
NADPH oxidase of neutrophils have a high Q~0. The 
BCECF experiments were carried out at 37°C. Second, in 
patch clamping in the cell-attached mode the cell cytosol is 
either replaced by or precipitated by the contents of the 
electrode. What effects this may have on channel activity 
is impossible to predict. The cytosol in the BCECF experi- 
ments was in the native state. The overall similarity in 
results obtained (Cd 2+, Zn 2 + inhibition, arachidonate elu- 
cidation) make it reasonable to assume that they are reflec- 
tions of the same channel activity and the differences arise 
from artifacts. 
Although the possibility that a rapid and transient depo- 
larisation to severely positive potential does occur, it has 
not been observed by the use of various dyes. It seems 
unlikely that the positive potentials required in the electro- 
physiological studies are obtained in vivo. 
7.6.1. Identification of the protein(s) which form and regu- 
late the H + channel 
The H + channel activity is vital for the activity of the 
oxidase. Full understanding of the oxidase therefore re- 
quires the identification of the protein(s) that function as 
and/or regulate the opening and functioning of the chan- 
nel. By definition it must be a transmembrane protein 
present in the plasma membrane of cells with oxidase 
activity, but not necessarily only those cells. The fact that 
both the oxidase and the channel are activated by arachi- 
donate could be taken to suggest that the channel is part of 
the oxidase complex. However, this does not necessary 
follow, as the non-synchronisation f initiation of the two 
processes maybe taken to suggest hat their activation is 
not a single event. 
Patch-clamping studies have identified an H + channel 
in differentiated HL60 cells [50]. In a later paper it was 
reported that undifferentiated HL60 cells did not have this 
activity [160]. The channel activity has also been shown to 
increase upon DMSO and DMF induced differentiation of 
HL60 cells to neutrophil-like cells as monitored by ApH 
changes and this paralleled the ability to generate superox- 
ide [83]. However, it should be noted that an increase in 
expression of a large number of proteins occurs. 
Grinstein and colleagues have monitored the pH~ 
changes of neutrophils isolated from CGD patients lacking 
the expression of various oxidase components. They de- 
duced that the channel is absent in the cells of patients 
lacking the expression of gp91-phox, or p22-phox, or 
p47-phox and was 50% of normal in a carrier of X-linked 
CGD [140]. It follows from their data that the activity of 
the channel is correlated with the activity of the oxidase. 
However, the authors failed to distinguish between the 
ability to generate superoxide and H + channel activity. 
According to their criteria, any defect in the superoxide- 
generating system would be seen as a defect in channel 
activity. These authors ubsequently completely eliminated 
the possible involvement of gp91-phox in the channel on 
the basis that neutrophils from a special X-linked CGD 
patient with a 10% expression of gp91-phox showed 70% 
of normal channel activity [141]. As the activity of the 
channel did not correlate with the level of gp91-phox 
expression, they concluded that it was not involved. How- 
ever, Orkin and colleagues have demonstrated that expres- 
sion of gp91-phox at 10% of normal was sufficient to 
achieve normal evels of superoxide generation when using 
gene therapy to restore oxidase activity in PLB-985 cells 
with a generated X-linked CGD phenotype [216]. By infer- 
ence it does not follow that the alterations in the level of 
protein expression will be absolutely matched by alter- 
ations in either or both oxidase and channel activity. 
Consequently, it would be highly unsafe to conclude that 
gp91-phox was not involved with the channel. 
Kaldi et al. [105] utilised a functional assay to explore 
the possible expression of the H + channel in pig lympho- 
cytes. They identified a PMA- and arachidonate-activatable 
H + channel activity in cells despite reporting that the cells 
do not generate superoxide. They concluded that the chan- 
nel was not an integral part of the oxidase, i.e., not one of 
the protein components [105]. However, Maly et al. [129] 
detected superoxide generation and the presence of cy- 
tochrome b in tonsillar lymphocytes and B cell lines. 
Therefore, as Kaldi et al. [105] did not monitor the expres- 
sion of gp91-phox, they cannot eliminate its involvement. 
Fully functional arachidonate activated H-  channel was 
demonstrated in EBV-transformed B lymphocyte cell lines 
derived from normal and CGD patients lacking the expres- 
sion of p47-phox and p67-phox but was absent in those 
cells lacking gp91-phox [83]. Therefore, in our hands, 
neither cytosolic factor regulates the activity of the chan- 
nel, but we cannot rule out the involvement of other, as yet 
unidentified, protein(s) in the regulation of the channel 
[83]. The inhibition by succinyl acetone of haem synthesis 
during the DMSO-induced differentiation of HL60 cells 
results in the absence of a stable p22-phox expression, 
while gp91-phox is unaffected. Since these cells exhibit a 
fully functional H ~ channel and the EBV lymphocytes 
lacking gp91-phox do not, it can be postulated that it is the 
absence of gp91-phox in the X-linked CGD cells which 
gives rise to the failure of channel activity. Chinese ham- 
ster ovary cells (CHO) transfected with gp91-phox cDNA 
show the expression of an arachidonate-activated H +
channel which correlates with the expression of gp91-phox. 
This channel is absent from control cells. It was shown 
immunologically that p22-phox, p47-phox and p67-phox 
were absent from both control and induced cells. These 
experiments provide clear evidence that gp91-phox is the 
only component of the oxidase involved in the functional 
channel. At present it cannot be excluded that the channel 
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is an unidentified protein expression of which is tightly 
coupled to and regulated by the expression of gp91-phox, 
even in Chinese hamster ovary cells [83]. 
Grinstein and Curnutte have recently suggested that the 
assembly of a fully functional oxidase is a prerequisite for 
channel activity [141]. This is not consistent with the 
results with Chinese hamster ovary cells reported above or 
with their own demonstration f a fully functional channel 
in cells from a CGD patient lacking expression of p67-phox. 
The statement by Grinstein and co-workers that a CGD 
patient lacking gp91-phox shows channel activity is con- 
tradicted by their data (Fig. 1 of [142]). 
8. Role of arachidonate in the activation of the NADPH 
oxidase 
The attainment of maximal rates of superoxide genera- 
tion by the NADPH oxidase takes less than 1 min with 
PMA and some 1-2 min with fMLP. The signal transduc- 
tion pathway leading to the activation of the oxidase is 
considered to consist of a membrane-bound receptor, a 
heteromeric GTP binding protein, a phosphoinositol spe- 
cific phospholipase C and a protein kinase C; see reviews 
[137,t85]. It is commonly stated that phosphorylation of
component(s) of the oxidase per se by protein kinase C is 
required for activation of the oxidase [6,25,68,92,95]. 
The addition of PMA or fMLP leads to the activation of 
the oxidase and to the phosphorylation f a wide range of 
proteins [96] In search of the specific target for phospho- 
rylation, Heyworth and Segal [92,178] identified a 47 kDa 
phosphoprotein which was not phosphorylated in autoso- 
mal CGD patients, but since, as was subsequently shown, 
the protein is absent from these patients, that is not surpris- 
ing. In normal neutrophils the protein was shown to 
translocate to the membrane following activation [93]. The 
ability of staurosporine (an inhibitor of protein kinases) to 
inhibit the PMA activation of superoxide generation and 
the phosphorylation of p47-phox supported the involve- 
ment of protein kinase C directed phosphorylation i  the 
activation of the nxidase [96]. It was therefore concluded 
that phosphorylation was the immediate activator of the 
oxidase. Dusi and Rossi [61] have shown a staurosporine- 
sensitive phosphorylation f p67-phox with similar conclu- 
sions. 
The amino acid sequence of p47-phox contains a num- 
ber of potential protein kinase C phosphorylation sites. 
Rotrosen and Leto [175] have isolated eight different phos- 
phorylated forms of p47-phox on two-dimensional e ec- 
trophoresis gels, based on variation in the isoelectric point. 
The shift in isoelectric point is considered to be due to the 
stepwise phosphorylation f the protein, corresponding to
eight different phosphorylation events. The addition of the 
3rd or 4th phosphate group was demonstrated to be associ- 
ated with the shift of the protein from the cytosolic to the 
membrane fraction of the cell and that the addition of the 
6th, 7th or 8th phosphate group resulted in a return of the 
protein to the cytosolic fraction. 
The PMA activation of the oxidase has a lag of 20 s and 
reaches a maximal rate of superoxide generation at 1 min 
after stimulation at 37°C. However, the phosphorylation f 
p47-phox, and other proteins, is barely detectable at 20 s 
and shows an accumulation over the following 10 min, 
when the activity of the oxidase is in decline. The stark 
differences in the time-courses for superoxide generation 
and that of p47-phox phosphorylation make very unlikely 
the correlation between the two processes claimed in Refs. 
[6,96,97]. 
If the phosphorylation f p47-phox or any other process 
is the direct activator of the oxidase, it "most probably" 
occurs under all conditions and circumstances in which the 
generation of superoxide is triggered and occurring. Bad- 
wey et al. [7,8] have shown that the retinal and 1,2-dioct- 
anoyl-sn-glycerol stimulation of superoxide generation by 
human neutrophils was not associated with the phosphor- 
ylation of p47-phox. The activation of the oxidase by 
arachidonate is completely insensitive to staurosporine and 
under these circumstances there is no increase in the 
incorporation of 32p into p47-phox or any other protein 
(with or without staurosporine) [89]. Under the same con- 
ditions, PMA stimulation was associated with an increase 
in phosphorylation f a wide range of proteins, including 
p47-phox. The failure to observe arachidonate-activated 
phosphorylation with and without staurosporine suggests 
that arachidonate and not phosphorylation is the immediate 
activator of the oxidase [89] and would appear to eliminate 
the possibility that the arachidonate activation is via PKC 
as has been suggested by McPhail et al. [133]. This 
conclusion is strongly supported by the findings of Dusi et 
al. [60]. They showed that translocation of p47- and p67- 
phox and superoxide generation were unaffected by stau- 
rosporine in Ca2+-depleted, fMLP and Con A activated 
neutrophils, whereas phosphorylation was very largely in- 
hibited. 
The addition of purified protein kinase and ATP to a 
cell-free reconstitution system failed to activate superoxide 
generation [39] arguing against a kinase-directed phosphor- 
ylation of an oxidase component as the immediate activa- 
tor of superoxide generation. However, arachidonate and 
other unsaturated fatty acids will activate the oxidase in 
whole cells [9,10], cytoplasts [89], the cell-free reconstitu- 
tion system [23,186] and in a system consisting of purified 
cytochrome b and recombinant cytosolic factors [1]. It has 
been suggested that the high levels of arachidonate r - 
quired in cell-free reconstitution systems (150 p,M) com- 
pared with the whole cells (8 ~M) is not consistent with 
arachidonate's role as a physiological activator. However, 
it has been shown recently that arachidonate p rforms two 
functions in the cell-free reconstitution system; first as a 
detergent to break up the membrane vesicles, allowing 
access to both faces of the membrane, and the second as an 
activator of the oxidase. When the first function is per- 
L.M. Henderson, J.B. Chappell / Biochimica et Biophysica Acta 1273 (1996) 87-107 101 
formed by a mild detergent, low concentrations of arachi- 
donate (10-15 /.LM) are required and are absolutely neces- 
sary for the activation of superoxide generation [99]. 
Phospholipase A 2 (PLA 2) is the enzyme which cleaves 
the fatty acid from carbon 2 of the glycerol backbone of 
the phospholipid generating a free fatty acid. The fatty 
acids on carbon 2 are normally unsaturated and predomi- 
nantly arachidonate in both phosphatidylinositol and phos- 
phatidylcholine. A number of different PLA 2 enzymes 
have been isolated (reviewed by [207]). The porcine pan- 
creatic 14 kDa PLA 2 has been widely studied and its 
properties have been invoked in models despite its obvious 
lack of involvement in stimulation-associated membrane 
lipid metabolism. A number of workers have recently 
isolated a cytosolic 85 kDa PLA 2 [31,51,116] which, 
because it is phosphorylated in association with activation 
in a number of different cells [28,56,124,125], is a better 
candidate for involvement in the stimulated release of 
unsaturated fatty acids in neutrophils. The role of and 
mechanisms triggering the activation of this PLA 2 in 
neutrophils is at present unknown, but could well be 
phosphorylation at the hands of an activator-stimulated 
protein kinase. 
The stimulation of the oxidase by a wide range of 
compounds is associated with an increase in the level of 
free arachidonate and other unsaturated fatty acids and in 
the subsequent production of leukotrienes and prosta- 
glandins. Release is generally monitored as radioactive 
counts released into the external aqueous environment of 
3H-arachidonate loaded cells. If the bulk of the liberated 
fatty acid is in the hydrophobic environment of the mem- 
brane it will not be recorded by this technique. This 
probably accounts for the small percentage total counts 
recovered by workers utilising this assay and hence the 
low assumed concentrations of free fatty acid. 
The PMA stimulation of superoxide generation was 
inhibited by a range of compounds thought o be inhibitors 
of porcine 14 kDa PLA 2. The inhibitors were equally 
effective whether added before or after PMA, but if added 
after PMA the activity was not immediately terminated but 
decreased in a time-dependent manner. In all cases, super- 
oxide generation was restored following the addition of 
arachidonate or SDS [90]. The mechanism of action of 
these inhibitors is not fully understood. They were de- 
signed around the active site of the X-ray crystallographic 
structure of pig pancreatic PLA 2 and they are effective at 
inhibiting the generation of free fatty acid in an in vitro 
assays. The common features of these inhibitors are a long 
hydrophobic saturated tail with a positively charged head- 
group. Stearylamine, which is very similar to these com- 
pounds, inhibits the PMA activation of superoxide genera- 
tion in a manner identical to the PLA 2 inhibitors. In the 
presence of stearylamine or a putative PLA 2 inhibitor, the 
generation of superoxide gradually recovers, in a time-de- 
pendent manner, suggesting the continuous generation of 
an activator which eventually overcomes the inhibition 
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Fig. 3. Stearylamine revisable inhibition of superoxide generation by 
cytoplasts. The generation of superoxide by PMA-stimulated cytoplasts, 
monitored as the reduction of superoxide, was inhibited in a concentration 
dependent manner by stearylamine. However, at all concentrations tested 
restoration of superoxide generation occurred some minutes following the 
addition of stearylamine, no further additions. The higher the concentra- 
tion of stearylamine the longer the time before the restoration of superox- 
ide was observed (a). The addition of either arachidonate or SDS to 
cytoplasts following inhibition by stearylamine immediately restores their 
ability to generate superoxide (b). 
(Fig. 3) (Henderson and Chappell, unpublished ata). We 
postulate that stearylamine and the putative PLA 2 in- 
hibitors are capable of binding free arachidonate, making it 
unavailable to the oxidase. In support of this suggestion, it 
has been shown by us that arachidonate and stearylamine 
form an extremely tight water-insoluble (in the/xM range) 
complex, which is extractable into hexane. 
Analogues of arachidonate have been described which 
are inhibitors of the cytosolic 85 kDa PLA 2. They are 
product analogues which competitively inhibit the enzyme 
by binding to the substrate binding site [193]. They are 
very slow-acting and in our hands fail to significantly 
inhibit superoxide generation. The nature of the PLA 2 
which is involved in the activation of the neutrophil oxi- 
dase is at present unknown. 
Cockcroft has proposed a role for a G protein in the 
activation of PLA 2, independent of that required to acti- 
vate PLC, but both receptor-linked [33]. The theory is 
based on a differential effect of pertussis toxin on the 
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fMLP-stimulated PLC and PLA z activities. However, it is 
difficult to see how PMA and other stimuli acting down- 
stream of a receptor could stimulate PLA 2 and hence the 
liberation of arachidonate. The evidence for a role for PKC 
in the activation of the oxidase is compelling. It is possi- 
ble, as stated previously, that the target is the activation of 
the 85 kDa PLA 2. 
Arachidonate and other unsaturated fatty acids are the 
only compounds which activate the oxidase in all assay 
systems, i.e., whole cells, cell-free system and in the 
purified recombinant protein assays; they are the only 
compounds which are unaffected by and can overcome the 
action of inhibitors of the signal transduction pathway such 
as staurosporine. Arachidonate stimulation of the oxidase 
is not associated with and does not require phosphoryla- 
tion. This strongly suggests that arachidonate is the imme- 
diate activator of the oxidase. Whether it acts through 
direct action upon one or more of the components of the 
oxidase or through changes in membrane fluidity surround- 
ing the cytochrome is at present unknown. However, 
arachidonate is a good candidate for a signal molecule, as 
it is readily liberated, has a number of pathways for its 
removal and is very unstable. 
An analysis of the fatty acids, unsaturated and their 
ester, amide and saturated erivatives demonstrated that 
the amide and ester forms of the unsaturated fatty acids 
were incapable of stimulating superoxide generation in a 
cell-free system despite the fact that their free fatty acid 
forms were fully active [123,186]. This suggests that acti- 
vation requires an unsaturated fatty acid with a free CO0 
group. The free CO0-  group may facilitate insertion into 
the membrane or it may be a requirement for the interac- 
tion with the protein components. As detergents alone are 
incapable of stimulating the oxidase [186], it is very un- 
likely that the activation by arachidonate can be exclu- 
sively ascribed to detergent properties and it is more likely 
that it is a direct effect upon oxidase component(s). 
9. Assembly of the active oxidase 
Received opinion is that superoxide generation requires 
the assembly of the oxidase complex by translocation of 
the cytosolic factors, p47-phox and p67-phox, to the mem- 
brane cytochrome b in the developing phagosome. The 
GTP binding protein also translocates to the membrane 
upon activation. 
The absence of translocation in cells from X-linked 
CGD patients and the translocation of p47-phox in the 
absence of p67-phox, but not vice versa, suggests an 
interaction between the cytochrome b and p47-phox in the 
active oxidase [94,95,149]. Rotrosen et al. [174] have 
reported the identification of a region in the C-terminal 14 
amino acids of gp91-phox which is required for the assem- 
bly of the active oxidase. Peptides containing the sequence 
RGVHFIF (amino acid 559-565 gp91-phox) inhibited the 
activity of the oxidase in a human neutrophil cell-free 
reconstitution system when the peptide was present before 
the addition of cytosolic proteins and arachidonate but not 
when added after assembly [111]. The inclusion of the 
peptide also appeared to prevent he phosphorylation of
p47-phox in a cell-free phosphorylation system [174]. 
Therefore, it was proposed that the C terminal of gp91-phox 
is the binding site for p47-phox in the active oxidase 
complex. The region of p47-phox responsible for this 
purported binding was not identified. However, we have 
failed to reproduce the result with this peptide in a cell-free 
system. Solutions of the peptide were highly acidic, possi- 
bly due to the presence of trifluoracetic acid (TFA), the 
eluant and counterion in the automatic synthesiser. Inhibi- 
tion similar to that reported by Rotrosen et al. [174] was 
achieved only if the pH of the peptide solutions remained 
acidic. This strongly suggests to us that the inhibition of 
the oxidase by this peptide arises from the acidity of the 
solution rather than the specific amino acid sequence of 
the peptide it contains. Neutralised peptide at high concen- 
tration was without effect. A solution of TFA alone was 
capable of inhibiting superoxide generation by a cell-free 
system ([88] and personal observation). Roos [168] has 
also noted that inhibition by peptides was due to the 
acidity of the solution and not the amino acid sequence of 
the peptide. Therefore, the direct interaction between p47- 
phox and gp91-phox is unproven. 
A wide range of proteins has now been identified which 
contain regions of homology with domains in the src 
kinase, i.e., SH2 and SH3 proteins. Some proteins contain 
either SH2, e.g., phosphoinositol specific phospholipase C 
[192], non-receptor tyrosine kinases or SH3 domains, e.g., 
GAP and p47-phox, p67-phox and possibly p40-phox 
[59,119,126,209,213], while adapter proteins, e.g., Grb2, 
drk (Drosophila eye), contain both SH2 and SH3 domains 
[150,177]. SH2 domains have been shown to bind 
phosphotyrosine-containing peptides [15] following the ac- 
tivation of receptor and associated tyrosine kinases, lead- 
ing to the activation of ras [63,67,122,177]. A proline-rich 
consensus equence (XPXXPPPq~XP) has been identified 
as the SH3 domain binding site in a number of proteins 
and the overall three-dimensional structure of the src SH3 
domain with and without the peptide bound has been 
determined [ 165]. The cytosolic factors p47-phox, p67-phox 
and the recently reported p40-phox each contain two pre- 
dicted SH3 domains. The C terminal of the amino acid 
sequence of p22-phox has a region of high homology to 
the proline-rich sequence which may be an SH3 binding 
site. Similar sequences are contained within p47-phox and 
possibly p67-phox but not gp91-phox [132]. In other sys- 
tems, the SH2 and SH3 domains have been proposed to be 
involved in protein interactions following activation. 
Therefore, it could be suggested that the SH3 domains may 
bind the subunits of the oxidase complex and therefore are 
involved in and direct the assembly of the active oxidase. 
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9.1. Possible role of SH3 domains in subunit nteractions 
Leto and co-workers [46] have investigated the role of 
the SH3 domains in the functioning of p67-phox, both in a 
cell-free reconstitution system and in an EBV-transformed 
cell line established from a CGD patient lacking p67-phox 
expression. Mutant protein in which either of first SH3 
domain or the second or both were deleted were con- 
structed. Also proteins containing only the N-terminal 246 
and the C terminal 296-457 amino acids were prepared. In 
the cell-free system superoxide generation in the presence 
of a mutant protein was more than 50% that of normal, 
even with the protein lacking both SH3 domains. How- 
ever, in the whole cells none of the mutant proteins was 
capable of supporting superoxide generation at a level 
greater than 10% of control. In both assay systems the 
deletion of the second, C terminal SH3 domain as opposed 
to the first, resulted in greater degree of inhibition, but 
whether this is due to a failure to bind because of the 
absence of an SH3 domain or because of a change in 
conformation is not clear. The difference between the 
results obtained from the two systems is striking and 
requires an explanation. The cell-free system lacks some of 
the components and certainly the organisation of the cyto- 
skeleton and other features. It has been suggested that the 
cytosolic factors are associated with the cytoskeleton and 
that the SH3 domains are involved in the binding to 
proteins of the cytoskeleton [119]. Therefore, it could be 
suggested that the role of the p67-phox SH3 domains is in 
its directed translocation to the plasma membrane via the 
cytoskeleton rather than in the interaction between sub- 
units. 
A number of workers have utilised isolated SH3 do- 
mains, expressed as glutathione-S-transferase fu ion pro- 
teins, immobilised on glutathione Sepharose, to investigate 
their ability to bind other proteins and the various proline 
rich regions. Finan et al. [64] demonstrated that the p67- 
phox C terminal SH3 domain bound to p47-phox when 
exposed to the detergent extract of differentiated HL60 
cells. The peptide KPQPAVPPRPSADL of the p47-phox 
C terminal proline-rich region was reported to inhibit 
completely this interaction at 750 /zM (K i 100 /~M). The 
underlined sequence is minimum core required for inhibi- 
tion. Similar interactions between glutathione-S-transferase 
fusion protein containing both p47-phox SH3 domains and 
the C terminus of p22-phox and p47-phox itself (residues 
70-83 and 358-390) were reported by Leto et al. [120]. 
The fusion proteins containing the SH3 domains individu- 
ally bound both p47-phox and p22-phox, but less avidly. 
The interaction with C terminus p22-phox was inhibited 
by the proline-rich peptide p22-phox (residues 149-162) 
and not observed with the p22-phox mutant Pro 156 --9 Gin 
[55] located in the proline-rich region. In an erythro- 
leukaemic cell line, K562, cotransfected with p22-phox 
and p47-phox a similar absence of translocation, following 
PMA stimulation, was observed with this p22-phox amino 
acid substitution mutant. Interestingly, normal PMA-in- 
duced translocation of p47-phox occurred in the presence 
of p22-phox but absence of gp91-phox, strongly indicating 
that gp91-phox is not essential for p47-phox binding to the 
membrane. In agreement with the above, Sumimoto et al. 
[194] also demonstrated aninteraction between the isolated 
C-terminal SH3 domain p67-phox and C-terminal proline- 
rich region (residues 358-390) of p47-phox. Therefore, 
SH3 domain-proline-rich region interactions have been 
described as occurring between p47-phox:p22-phox; p47- 
phox:p47-phox; p47-phox:p67-phox. Since superoxide 
generation requires activation, these data do not necessar- 
ily demonstrate interactions in the assembled, active oxi- 
dase but more likely describe the state in the unstimulated 
cell, in a possible cytosolic complex. Of these, the p47- 
phox:p22-phox interaction is probably most relevant in 
PMA-activated cells. 
The src kinase C terminal proline-rich sequence is 
reported to be bound to its own SH3 domain in the 
inactive kinase. Activation is thought o break the interac- 
tion, thus allowing binding to other proteins and potential 
substrates. It is therefore possible that proline-rich se- 
quences of the p47-phox could bind its SH3 domains in 
the unstimulated cell. Thus, it could be suggested that 
activation would involve an alteration in p47-phox confor- 
mation, exposing its SH3 domains and thereby promoting 
its interaction with the C-terminal proline-rich region of 
p22-phox. That stimulation of the oxidase may indeed 
induce conformation change of this nature is suggested by 
the selective binding of a monoclonal antibody to the 
p47-phox SH3 domain. Although the monoclonal antibody 
recognised glutathione-S-transferase fused to SH3-SH3 
p47-phox domains (residues 154-285) in the presence or 
absence of arachidonate [194], its ability to bind p47-phox 
was totally dependent upon the presence of 50 /zM arachi- 
donate or 100 /zM SDS. The glutathione-S-transferase- 
SH3 fusion protein was shown to bind to p47-phox (re- 
sidues 286-390) C-terminal, proline-rich region. This sug- 
gests that in the unstimulated native p47-phox the SH3 
domains are inaccessible to the monoclonal antibody due 
to intramolecular interaction(s). In agreement with this, 
Leto et al. [120], Sumimoto et al. [194] demonstrate an 
interaction between the glutathione-S-transferase-SH3 
p47-phox and the GST-C terminal p22-phox fusion protein 
(residues 145-170) which was not observed with the 
Pro ~56 ~ Gin mutant. The SH3 binding site was narrowed 
down to a 10-amino-acid core, PPSNPPPRPP. Binding of 
p47-phox to p67-phox was also described to be arachi- 
donate- or SDS-dependent. 
Fuchs et al. [65] have recently described interactions 
between p40-phox and both p47-phox and p67-phox. The 
SH3 domain of p40-phox (base 565 to the stop codon) was 
shown to interact with p47-phox and C-terminus p40-phox 
with p67-phox. 
We can therefore conclude that there is some evidence 
that the SH3 domain-proline-rich regions probably play a 
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role in the regulation of the oxidase component interac- 
tions, both in the inactive and stimulated cells, and that 
arachidonate plays an important role. 
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